AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27839981 — intervention group
Group type: COMPARATOR
Intervention: Taliglucerase alfa (dose as previously treated with imiglucerase)
Number of subjects: 15
Study 26869678 — intervention group
Group type: COMPARATOR
Intervention: PRM‐151 (recombinant human pentraxin‐2) at doses of 1, 5, or 10 mg·kg(‐1) administered intravenously on days 1, 3, 5, 8, and 15.
Number of subjects: 0
Study 26869678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24462229 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT-arm)
Number of subjects: 90
Study 24462229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-brief pulse continuation electroconvulsive therapy (ECT-arm)
Number of subjects: 90
Study 24462229 — intervention group
Group type: COMPARATOR
Intervention: No add-on therapy (MED-arm)
Number of subjects: 90
Study 22823477 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and promotion of target-driven, intensive treatment of multiple risk factors (n = 1678 patients)
Number of subjects: 3057
Study 22823477 — intervention group
Group type: COMPARATOR
Intervention: Screening plus routine care (n = 1379 patients)
Number of subjects: 3057
Study 20666799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribose cross‐linked (RCL) collagen membrane
Number of subjects: 20
Study 20666799 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde cross‐linked (GCL) collagen membrane
Number of subjects: 20
Study 20666799 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐cross‐linked (NCL) collagen membrane
Number of subjects: 20
Study 17825197 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment combined with laparoscopy and digital subtraction angiography (group B)
Number of subjects: 75
Study 17825197 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (group A)
Number of subjects: 75
Study 15928469 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression device with impedance threshold device
Number of subjects: 372
Study 15928469 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-Pulse CPR
Number of subjects: 372
Study 12088807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiopental, 5 mg/kg (25 microg/kg/min)
Number of subjects: 27
Study 12088807 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic propofol, 1.25 mg/kg (50 microg/kg/min)
Number of subjects: 27
Study 12088807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nongeneric propofol, 1.25 mg/kg (50 microg/kg/min)
Number of subjects: 27
Study 12088807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiopental or propofol (generic and nongeneric)
Number of subjects: 27
Study 12088807 — intervention group
Group type: COMPARATOR
Intervention: Generic propofol
Number of subjects: 27
Study 12088807 — intervention group
Group type: COMPARATOR
Intervention: Nongeneric propofol
Number of subjects: 27
Study 9793192 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin stimulation in women with PCOS
Number of subjects: 22
Study 9793192 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin stimulation in normally ovulating women (control group)
Number of subjects: 22
Study 8132701 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumarin (50 mg daily for 2 years)
Number of subjects: 27
Study 8132701 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 27
Study 2510561 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg intravenous flumazenil repeated every minute until fully awake (mean 4.5 +/- 2.6 micrograms.kg‐1)
Number of subjects: 24
Study 2510561 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous recovery without flumazenil
Number of subjects: 24
Study 31964419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 1118
Study 31424410 — intervention group
Group type: EXPERIMENTAL
Intervention: CT+Active tDCS (2mA for 30min and 0.016mA for 30min)
Number of subjects: 68
Study 31424410 — intervention group
Group type: COMPARATOR
Intervention: CT+Sham tDCS (0.016mA for 60min)
Number of subjects: 68
Study 28568608 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg at bedtime (acute dose)
Number of subjects: 72
Study 28568608 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 200 mg after chronic dosing (supratherapeutic dose)
Number of subjects: 72
Study 28568608 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg (positive control)
Number of subjects: 72
Study 28568608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 25689859 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oils
Number of subjects: 15
Study 25689859 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 15
Study 25689859 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (negative control)
Number of subjects: 15
Study 23756546 — intervention group
Group type: EXPERIMENTAL
Intervention: PhysioGlove (PG)
Number of subjects: 428
Study 23756546 — intervention group
Group type: COMPARATOR
Intervention: Standard-cable electrocardiograms
Number of subjects: 428
Study 21272154 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine treatment for 6 months
Number of subjects: 33
Study 19151286 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL of lidocaine 15 mg/mL with epinephrine 5 microg/mL
Number of subjects: 40
Study 19151286 — intervention group
Group type: COMPARATOR
Intervention: 3 mL of saline IV
Number of subjects: 40
Study 16703746 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CRT boost to 24 Gy (group III)
Number of subjects: 36
Study 16703746 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CRT boost to 20 Gy (group II)
Number of subjects: 36
Study 16703746 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CRT boost to 16 Gy (group I)
Number of subjects: 36
Study 16703746 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CRT boost technique
Number of subjects: 36
Study 15045199 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ablation for liver tumors
Number of subjects: 182
Study 15045199 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ablation for non-hepatic tumors
Number of subjects: 182
Study 15045199 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ablation overall
Number of subjects: 182
Study 9832744 — intervention group
Group type: EXPERIMENTAL
Intervention: Roho mattresses
Number of subjects: 100
Study 9832744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofflex mattresses
Number of subjects: 100
Study 9832744 — intervention group
Group type: EXPERIMENTAL
Intervention: Roho Quatro cushions
Number of subjects: 100
Study 9832744 — intervention group
Group type: COMPARATOR
Intervention: Roho mattresses and Sofflex mattresses
Number of subjects: 100
Study 8080678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron + Dexamethasone
Number of subjects: 160
Study 8080678 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron + Placebo
Number of subjects: 160
Study 8080678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 160
Study 2678804 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial thrombectomy and elastic compression (EC)
Number of subjects: 83
Study 2678804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca Heparin (0.5 mgs b.i.b.) + EC
Number of subjects: 83
Study 2678804 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoruton (1 g, t.i.d.) + EC
Number of subjects: 83
Study 2678804 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoruton (1 g, t.i.d.) after superficial thrombectomy + EC
Number of subjects: 83
Study 2678804 — intervention group
Group type: COMPARATOR
Intervention: Elastic compression (EC)
Number of subjects: 83
Study 175146 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative (ego threat) presleep condition (n=14)
Number of subjects: 31
Study 175146 — intervention group
Group type: COMPARATOR
Intervention: Positive presleep condition (n=17)
Number of subjects: 31
Study 175146 — intervention group
Group type: EXPERIMENTAL
Intervention: Low neuroticism subjects in the negative condition
Number of subjects: 31
Study 175146 — intervention group
Group type: EXPERIMENTAL
Intervention: Low neuroticism subjects in the positive condition
Number of subjects: 31
Study 31735039 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirituality (measured by FACIT total scores)
Number of subjects: 210
Study 31735039 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT scores
Number of subjects: 210
Study 27871220 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet Eye Training (QET)
Number of subjects: 30
Study 27871220 — intervention group
Group type: COMPARATOR
Intervention: Traditional Training (TT)
Number of subjects: 30
Study 25496399 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month lifestyle intervention (pedometer, weight scale, asthma education DVD, and information about weight management services)
Number of subjects: 330
Study 25496399 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month lifestyle intervention
Number of subjects: 330
Study 25496399 — intervention group
Group type: COMPARATOR
Intervention: usual care (pedometer, weight scale, asthma education DVD, and information about weight management services)
Number of subjects: 330
Study 25496399 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 330
Study 23247114 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 23
Study 23247114 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 23
Study 23247114 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ET and RT
Number of subjects: 23
Study 22024104 — intervention group
Group type: EXPERIMENTAL
Intervention: WATCH IT intervention for childhood obesity
Number of subjects: 70
Study 22024104 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referral via media promotion
Number of subjects: 70
Study 18726153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg once daily
Number of subjects: 241
Study 18726153 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 241
Study 17988379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 2 g before and after intervention
Number of subjects: 165
Study 17988379 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 165
Study 15076628 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis strain Bb 12 (BbF)
Number of subjects: 90
Study 15076628 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula (CF)
Number of subjects: 90
Study 11755326 — intervention group
Group type: COMPARATOR
Intervention: TENS turned off
Number of subjects: 40
Study 11755326 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS activated
Number of subjects: 40
Study 9388128 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg lovastatin for 6 months
Number of subjects: 0
Study 8189778 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (FI)
Number of subjects: 2725
Study 8189778 — intervention group
Group type: COMPARATOR
Intervention: Limited intervention (LI)
Number of subjects: 2725
Study 31232840 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard occlusive dressing method (hydrogel or alginate and hydrocolloid compounds)
Number of subjects: 60
Study 31232840 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dressing method (transparent hydrocolloid films replaced by Vaseline gauze)
Number of subjects: 60
Study 31232840 — intervention group
Group type: COMPARATOR
Intervention: Control group (gauze swabs soaked in normal saline)
Number of subjects: 60
Study 28727955 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-oriented dietary intervention
Number of subjects: 0
Study 28727955 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25936632 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin-rifampicin
Number of subjects: 34
Study 25936632 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin-levofloxacin (control)
Number of subjects: 34
Study 25936632 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 23380428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine PIC® 4 mg
Number of subjects: 36
Study 23380428 — intervention group
Group type: COMPARATOR
Intervention: Sirdalud® 4 mg
Number of subjects: 36
Study 20655664 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 16
Study 20655664 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 16
Study 18435375 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine‐gluconate‐based cavity disinfectant
Number of subjects: 126
Study 18435375 — intervention group
Group type: COMPARATOR
Intervention: No chlorhexidine‐gluconate‐based cavity disinfectant
Number of subjects: 126
Study 16941685 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b (1.5 microg/kg) monotherapy
Number of subjects: 38
Study 16941685 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b (1.5 microg/kg) in combination with ribavirin
Number of subjects: 38
Study 16941685 — intervention group
Group type: COMPARATOR
Intervention: Follow-up after treatment
Number of subjects: 38
Study 14613633 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ivermectin (lotion)
Number of subjects: 108
Study 14613633 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiabendazole (ointment and lotion)
Number of subjects: 108
Study 14613633 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (lotion)
Number of subjects: 108
Study 14613633 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 108
Study 10731624 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 183
Study 10731624 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 183
Study 10731624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 9363714 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle stimulating hormone (FSH) therapy
Number of subjects: 81
Study 9363714 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 81
Study 1389519 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 600 mg/m2 plus leucovorin (LV) 500 mg/m2
Number of subjects: 148
Study 1389519 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) 600 mg/m2 alone
Number of subjects: 148
Study 3159698 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 30
Study 3159698 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 30
Study 30897303 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Viral Load (RVL) monitoring every six months
Number of subjects: 647
Study 30897303 — intervention group
Group type: COMPARATOR
Intervention: Targeted Viral Load (TVL) strategy (routine CD4 plus VL testing if clinical or immunological failure)
Number of subjects: 647
Study 29377807 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Tongue Drive System (mTDS)
Number of subjects: 15
Study 29377807 — intervention group
Group type: COMPARATOR
Intervention: Keyboard-and-mouse (KnM)
Number of subjects: 15
Study 26671307 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP for 2 weeks
Number of subjects: 30
Study 26671307 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic CPAP (withdrawal of treatment) for 2 weeks
Number of subjects: 30
Study 24736801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependence Scale (DS)
Number of subjects: 0
Study 22304968 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and Alternative Medicine (CAM) treatments
Number of subjects: 1004
Study 22304968 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1004
Study 20554710 — intervention group
Group type: EXPERIMENTAL
Intervention: naive acromegaly patients
Number of subjects: 16
Study 20554710 — intervention group
Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 16
Study 17391505 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 610
Study 17391505 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 610
Study 17391505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 16275967 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral therapy with magnesium oxide, Lactobacillus acidophilus, and simethicone
Number of subjects: 128
Study 16275967 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydration, nasogastric-tube decompression and nothing by mouth (control)
Number of subjects: 128
Study 16275967 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study 16275967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 128
Study 12197983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (written recommendations, technical assistance, and worker training)
Number of subjects: 48
Study 12197983 — intervention group
Group type: COMPARATOR
Intervention: Comparison (written recommendations alone)
Number of subjects: 48
Study 9527206 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 70
Study 9527206 — intervention group
Group type: COMPARATOR
Intervention: Control (no ischemic preconditioning)
Number of subjects: 70
Study 7630075 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral catheter feeding using Inpitan, ovolact, and hypernutril administered via the nasal passage into the proximal segment of the jejunum starting 5 to 7 days after the operation.
Number of subjects: 60
Study 7630075 — intervention group
Group type: COMPARATOR
Intervention: Parenteral feeding (Control group).
Number of subjects: 60
Study 2294793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg every 6 hours)
Number of subjects: 52
Study 2294793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31875737 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cord clamping (ICC)
Number of subjects: 38
Study 31875737 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping (DCC)
Number of subjects: 38
Study 31875737 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ICC and DCC)
Number of subjects: 38
Study 30468636 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed models
Number of subjects: 2
Study 30468636 — intervention group
Group type: COMPARATOR
Intervention: MRI images
Number of subjects: 2
Study 29188854 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nutraceuticals based on Bacopa monnieri, L‐theanine, Crocus sativus, copper, folate and vitamins of B and D group
Number of subjects: 30
Study 29188854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25716777 — intervention group
Group type: EXPERIMENTAL
Intervention: DM60 (60mg/day dextromethorphan)
Number of subjects: 196
Study 25716777 — intervention group
Group type: EXPERIMENTAL
Intervention: DM120 (120mg/day dextromethorphan)
Number of subjects: 196
Study 25716777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 23475700 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired relaxation (LV-IR), n = 15
Number of subjects: 45
Study 23475700 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudonormal or restrictive (LV-P/R), n = 15
Number of subjects: 45
Study 23475700 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal function (LV-NF), n = 15
Number of subjects: 45
Study 23475700 — intervention group
Group type: COMPARATOR
Intervention: Control group (N), n = 14
Number of subjects: 45
Study 21425510 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (cFNB) with ropivacaine 0.2% from surgery until the following morning, then continued with perineural ropivacaine for 4 days (n=28)
Number of subjects: 54
Study 21425510 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group, n=26)
Number of subjects: 54
Study 18774567 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg sublingual misoprostol
Number of subjects: 105
Study 18774567 — intervention group
Group type: COMPARATOR
Intervention: Manual vacuum aspiration (control)
Number of subjects: 105
Study 17239711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin infusion
Number of subjects: 76
Study 17239711 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 76
Study 14633525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate solution (25 mL/kg, mean 1565 mL) infused over 15, 30, 45, and 80 min
Number of subjects: 5
Study 10708287 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir monotherapy (100, 300 or 600 mg twice daily)
Number of subjects: 60
Study 10708287 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine/zidovudine combination therapy
Number of subjects: 60
Study 10708287 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir monotherapy
Number of subjects: 60
Study 10708287 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir with mutations
Number of subjects: 60
Study 10708287 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir with single mutations
Number of subjects: 60
Study 9083598 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing curriculum plus the intervention curriculum
Number of subjects: 1657
Study 9083598 — intervention group
Group type: COMPARATOR
Intervention: Existing curriculum
Number of subjects: 1657
Study 8415473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (T) 37.5 mg/day
Number of subjects: 83
Study 8415473 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline (M) 75 mg/day
Number of subjects: 83
Study 8415473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (T) with Hormone Replacement Therapy (HRT)
Number of subjects: 83
Study 8415473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (T)
Number of subjects: 83
Study 3533086 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen syrup 200 mg
Number of subjects: 60
Study 3533086 — intervention group
Group type: COMPARATOR
Intervention: Metamizole syrup 500 mg
Number of subjects: 60
Study 30397963 — intervention group
Group type: EXPERIMENTAL
Intervention: Disaster educational program for nursing students
Number of subjects: 60